Alta Sciences

DECEMBER 31, 2024

In Issue 7 of The Altascientist , we delve into these factors, the importance of drug interaction studies, and how to limit adverse effects and maximize treatment response. In some cases, these side effects could be life-threatening, such as drops in blood pressure, irregular heartbeats, or organ damage.

Therapies 52

Therapies Pharmacokinetics Pharmacogenetics Clinical Trials 52

DrugBank

JULY 14, 2025

Understanding the pharmacokinetics and pharmacodynamics of each drug in these complex regimens is critical to ensure safe and effective treatment.  Pharmacogenetic testing identifies individuals with genetic variants that influence the metabolism of drugs, allowing for personalized dose adjustments.

Clinical Development 52

Clinical Development Pharmacokinetics Drugs Clinical Trials 52

ASPET

SEPTEMBER 16, 2024

GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Acknowledging the potential for inter-species differences in pharmacokinetics, these data suggest that clinical translation of elimusertib in combination with temozolomide for treatment of GBM may be limited.

Pharmacogenetics 100

Pharmacogenetics DNA Treatment Pharmacokinetics 100

ASPET

FEBRUARY 26, 2024

Panobinostat is a potent pan-HDAC inhibitor that has been tested in multiple studies for the treatment of brain tumors. There have been contrasting views surrounding its efficacy for the treatment of tumors in the CNS following systemic administration when examined in different models or species.

Metabolic Stability 100

Metabolic Stability Pharmacokinetics Pharmacogenetics Treatment 100

ASPET

OCTOBER 12, 2023

Panobinostat is a nonselective pan-HDAC inhibitor that is being tested in pre-clinical and clinical studies, including for the treatment of pediatric medulloblastoma, which has a propensity for leptomeningeal spread, and diffuse midline glioma (DMG), which can infiltrate into supratentorial brain regions.

Pharmacogenetics 100

Pharmacogenetics Clinical Trials Treatment Therapies 100

ASPET

MARCH 6, 2024

The contrary was observed, when microsomes isolated from treatment naive animals were assessed for the OSI-420 formation after erlotinib exposure. Microsomes isolated from the treated animals were characterized for CYP3A activity using testosterone, showing higher activity in the knock-in rats.

Protein Expression 100

Protein Expression Pharmacogenetics Treatment Drugs 100

The Open Targets Blog

NOVEMBER 30, 2023

Introducing pharmacogenetics data to the Platform This release introduces a new datasource to the Platform: the pharmacogenetics widget will incorporate data about the impact of human genetic variation on drug responses. You can find this data on the target and drug profile pages.

Pharmacogenetics 57

Pharmacogenetics Small Molecule Disease Drugs 57